WASHINGTON: Pfizer Inc.
Chief Executive Officer Albert Bourla said on Monday he was unsure about the need for the fourth dose of Covid-19 vaccine and that a shot that targeted a very contagious Omicron variant would be ready in March.
The comment was contrasted by which made by Moderna Inc.
CEO Stephen Bancel, who said last week people could need another shot in the fall of 2022 because the booster’s efficacy would decrease over the next few months.
A large surge driven by Omicron in the case of Covid-19 has forced several countries to see other booster doses, but the initial signs show recurring vaccination may be a difficult selling because the population is expected to enter their third pandemic year.
“I don’t know if there is a need for the fourth booster, it is something that needs to be tested,” Bourla said about CNBC, ahead of the Pfizer presentation at J.
P.
Morgan Healthcare Conference.
The work is underway in the new version of Covid-19 vaccines that will be effective against Omicron and other variants, he said.
Us.
The previous day announced three agreements to expand the use of Messenger RNA Technology (MRNA) based on the Covid-19 vaccine, including a pact as much as $ 1.35 billion with gene editing specialist therapy.
Pfizer has been looking to advance the development of mRNA and therapeutic-based vaccines after leading global efforts to develop Covid-19 shots against pandemics.
The company will also collaborate with Codex DNA Inc.
to utilize exclusive biotech technology, which can enable more efficient, therapeutic, therapeutic, therapeutic, and other biofarma products.
This dealing with private biotech Acuitas Therapeutics will focus on the use of vancouver-based lipid nanoparticle technology to develop up to ten vaccines or therapy.